NCT00621712

Brief Summary

The study investigates the efficacy of a catheter with antibacterial surface coating in preventing central venous catheter related infection and the effect of an intensive hygiene and catheter care education of the nursing staff on preventing central venous catheter-related infection.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
90

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Oct 2007

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2007

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

January 31, 2008

Completed
22 days until next milestone

First Posted

Study publicly available on registry

February 22, 2008

Completed
2.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2010

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2010

Completed
Last Updated

March 13, 2025

Status Verified

March 1, 2025

Enrollment Period

3.2 years

First QC Date

January 31, 2008

Last Update Submit

March 11, 2025

Conditions

Keywords

Renal DialysisDialysis, ExtracorporealDialysis, RenalExtracorporeal Dialysis

Outcome Measures

Primary Outcomes (1)

  • Bacterial colonisation of the catheter surface

    at explantation

Secondary Outcomes (4)

  • Surface deposits of thrombogenic activity

    at explantation

  • Catheter survival

    at explantation

  • Exit site appearance

    at routine catheter care

  • Blood parameters

    during dialysis

Study Arms (2)

A

ACTIVE COMPARATOR

Patients in group A will be provided with a commercially available and CE certified standard double lumen catheter without surface coating (GamCath® catheter, No. CE 76891).

Device: GamCath® central venous catheter

B

EXPERIMENTAL

Patients in group B will be treated with a CE certified double lumen catheter with a new antibacterial bismuth-containing surface coating (GamCath Dolphin® Protect, No. CE 90671).

Device: GamCath Dolphin® Protect central venous catheter

Interventions

choice of catheter type

Also known as: GamCath® catheter, No. CE 76891
A

choice of catheter type

Also known as: GamCath Dolphin® Protect, No.CE 90671
B

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • central venous catheter placement
  • Need for extracorporeal renal replacement therapy (acute and chronic renal failure)
  • Age over 18 years
  • Written informed consent
  • Needed catheter length 15 cm or 20 cm

You may not qualify if:

  • Known infectivity with Hepatitis B Virus (HBV)/Hepatitis C Virus (HCV)/Human Immunodeficiency Virus (HIV)
  • Any infection associated with one or more positive blood cultures within 10 days prior to catheter implantation
  • Bacteremia with a former catheter within 10 days prior to catheter implantation
  • Known pregnancy
  • Lactation
  • Participation in another clinical study during the preceding 30 days

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

St. Joseph-Krankenhaus Berlin

Berlin, 12101, Germany

Location

Related Publications (1)

  • Schults JA, Kleidon T, Charles K, Young ER, Ullman AJ. Peripherally inserted central catheter design and material for reducing catheter failure and complications. Cochrane Database Syst Rev. 2024 Jun 28;6(6):CD013366. doi: 10.1002/14651858.CD013366.pub2.

MeSH Terms

Conditions

Renal Insufficiency

Condition Hierarchy (Ancestors)

Kidney DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital Diseases

Study Officials

  • Christiane M Erley, Prof. Dr.

    St. Joseph-Krankenhaus Berlin

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 31, 2008

First Posted

February 22, 2008

Study Start

October 1, 2007

Primary Completion

December 1, 2010

Study Completion

December 1, 2010

Last Updated

March 13, 2025

Record last verified: 2025-03

Locations